NCT05922384招募中不适用
Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma
Affiliated Hospital of Guangdong Medical University1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2023年7月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
This pilot clinical trial studies gene therapy in treating patients with HIV-1 infecetion combined with lymphoma undergoing 7shRNA lentiviral vector transduced CD34+ hematopoietic stem cell transplant. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, CD34+hematopoietic stem cells are mobilized and collected from the patient's peripheral blood. The CD34+stem cells are then isolated and transduced with lenti-7shRNA vector and reinfused to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
详细描述
Primary objectives:
- To determine the safety and feasibility of using lenti-7shRNA transduced hematopoietic stem/progenitor cells in the setting of autologous hematopoietic cell transplantation for treatment of HIV infection combined with lymphoma. The safety of the genetically modified product used in the transplant procedure will be assessed by monitoring each subject for adverse events (procedure related toxicity); absolute neutrophil count (ANC)/platelet engraftment (sustained recovery); and evidence of replication competent vector or vector recombination with the human immunodeficiency virus (HIV) quasi-species present in the patient.
- To determine the quantity and duration of vector-marked peripheral blood cells and to characterize: the duration and level of gene marking and expression of the anti-HIV shRNA in these transduced cells, and the characterization of the integration sites of vector sequences in circulating cells if there is a clinical syndrome suggestive of a clonal expansion of hematopoietic cells. In addition, the feasibility of the process will be assessed based on the results of the release testing of the transduced cells prior to injection into the patient.
- To measure the effect of HIV infection on the presence of HIV-resistant blood cells as measured by genetic marking for vector sequences before and after antiviral treatment interruption.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body mass index (BMI) 18-25, body weight should be ≥ 40kg;
- •Meet the Diagnostic Criteria for AIDS and HIV Infection (WS293-2019), and be diagnosed as HIV seropositive;
- •HIV infection combined with lymphoma, in partial remission or relapsed after initial complete remission, failed induction therapy, but responds to salvage therapy;
- •Age-adjusted IPI 2-3 points;
- •Meet the indications for autologous bone marrow transplantation after clinical evaluation;
- •HIV viral load <1000 copies/ml;
- •Must have the ability to understand and the willingness to sign a written informed consent.
排除标准
- •Any HIV-related uncontrolled opportunistic infection, including fungal infection, sepsis, active tuberculosis, weightlessness, severe diarrhea, active opportunistic infections in the central nervous system or active hepatitis B, hepatitis C, and other viral infections such as CMV;
- •Cardiac insufficiency (LVEF<50%), renal insufficiency (creatinine>2mg/dl), hepatic insufficiency (AST/ALT>3 ULN and/or PT <70% unrelated to lymphoma);
- •HAART treatment failure (including at least one NRTI, one NNRTI and two PI) and/or CD4 count < 50/cmm);
- •Malignancy other than lymphoma, unless (1) in complete remission and more than 5 years from last treatment, or (2) cervical/anal squamous cell carcinoma in situ or (3) superficial basal cell and squamous cell cancers of the skin;
- •Participation of other investigational agents (traditional Chinese medicine is not included) within 3 months；
- •Any concurrent or past medical condition that, in the opinion of the Investigator, would exclude the subject from participation or any psychosocial conditions that would hinder study compliance or follow-up, at the discretion of the Investigator.
研究组 & 干预措施
7shRNA modified CD34+stem cells
Experimental
Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines and then received hematopoietic stem cell transplant on day 0
干预措施: KL-7SHRNA injection solution (Drug)
结局指标
主要结局
Overall survival
时间窗: D0 post-infusion to completion of follow-up, an average of 2 year
Number of patients alive all over the trial
Engraftment time of 7shRNA modified CD34+ stem cells
时间窗: within day +28 after gene therapy
Haematological engraftment is defined as first day of neutrophil count \>500/mm3 and platelets \>20,000/mm3 on 7 consecutive blood counts.
次要结局
- 7shRNA VCN(At week 2, months 1, 2, 3, 4, 5, 6, 7, 8, 9，10,12，15,18,21and 24 post-transplant)
- Duration of interruption of HAART(Up to 24 months post-treatment)
- Transplantation related mortality(Up to 24 months post-treatment)
研究者
Jinqi Huang
Director of Hematology Department
Affiliated Hospital of Guangdong Medical University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain TumorsSupratentorial Neoplasms, MalignantMalignant GliomaAnaplastic AstrocytomaCerebral Primitive Neuroectodermal TumorEmbryonal TumorGlioblastomaPNETNCT02457845Gregory K. Friedman, MD13
撤回
2 期
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade GliomaNeoplasmsHigh Grade GliomaMalignant Glioma of BrainAnaplastic Astrocytoma of BrainHigh-grade GliomaAnaplastic GliomaGiant Cell GlioblastomaGlioblastoma MultiformeNCT04482933Pediatric Brain Tumor Consortium35
已完成
4 期
Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV SubjectsHIVHIV InfectionsNCT00966329Germans Trias i Pujol Hospital30
已完成
1 期
A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)Human Immunodeficiency VirusAIDS VirusNCT03615183Merck Sharp & Dohme LLC17
进行中（未招募）
1 期
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantHIV InfectionMature T-Cell and NK-Cell Non-Hodgkin LymphomaPlasmablastic LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Follicular LymphomaStage III Follicular LymphomaStage III Mantle Cell LymphomaStage IV Follicular LymphomaStage IV Mantle Cell LymphomaNCT02797470AIDS Malignancy Consortium11